Prognostic significance of X-ray cross-complementing gene 1 expression in gastric cancer

• Published in: Chinese journal of cancer research Vol. 28; no. 3; pp. 355 - 361
• Main Authors: Wang, Jian, Wang, Tongshan, Xu, Jun, Chen, WenJiao, Shi, Wei, Cheng, Jianfeng, Liu, Ping, Zhou, Xiqiao
• Format: Journal Article
• Language: English
• Published: China Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center, Nanjing Medical University, Nanjing 210029, China%Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China%Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China%Carolinas Medical Center, University of North Carolina Charlotte Campus, Charlotte, NC 28203, USA 01.06.2016; Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; AME Publishing Company
• Subjects: DNA修复; Original; X射线; 互补; 免疫组织化学; 基因; 多因素分析; 胃癌; 预后; Gastric cancer; X-ray cross-complementing gene 1 (XRCC1); platinum drugs prognosis; X-ray cross-complementing gene 1(XRCC1)
• ISSN: 1000-9604; 1993-0631
• DOI: 10.21147/j.issn.1000-9604.2016.03.10

Objective： The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 （XRCCI） in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. Methods： Immunohistochemistry （IHC） was used to evaluate XRCCI protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival （DFS） and overall survival （OS） were analyzed. Results： Among 612 patients staged II/III in our study, 182 （29.74%） were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS （P=0.347） or DFS （P=0.297）. Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS （P=0.031）. And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy （P=0.049）. Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS （P〈0.05）. Though XRCCI plays an important role in DNA repair pathways, no significant relationship is found in XRCCI expression and OS among gastric cancer in our study. Conclusions： XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.